Financials in USD. Standardized financial statements.
A compact view of how Oncternal Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $785,000 | $1.49M | $4.32M | $3.38M | $2.42M | $2.52M | $1.67M | -$2.51M | $0 | $0 |
| Revenue Growth? | -47.3% | -65.5% | +27.9% | +39.2% | -3.8% | +50.6% | +166.7% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $29.75M | $179,000 | $169,000 | $12.00M | $10.16M | $46,000 | $47,000 | $2.51M | $43,000 | $0 |
| Gross Profit? | -$28.97M | $1.31M | $4.15M | -$8.63M | -$7.73M | $2.48M | $1.63M | -$5.02M | -$43,000 | $0 |
| Gross Margin? | -3690.2% | +88.0% | +96.1% | -255.6% | -318.9% | +98.2% | +97.2% | +200.0% | 0.0% | 0.0% |
| Operating Expenses? | $12.75M | $44.95M | $31.37M | $17.54M | $15.02M | $39.06M | $30.66M | $25.93M | $21.84M | $30.35M |
| Operating Income? | -$41.71M | -$44.95M | -$31.37M | -$17.54M | -$33.11M | -$39.06M | -$30.66M | -$25.93M | -$21.84M | -$30.35M |
| EBITDA? | $2.23M | -$44.95M | -$31.16M | -$17.39M | -$33.11M | $1.01M | -$30.39M | -$17.70M | -$18.66M | -$39.31M |
| Income Before Tax | -$39.48M | -$44.17M | -$31.33M | -$17.23M | -$34.19M | -$38.42M | -$30.44M | -$17.72M | -$18.70M | -$39.41M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $641,000 | -$47,000 | $0 | $0 | $0 |
| Net Income? | -$39.48M | -$43.39M | -$31.30M | -$17.21M | -$15.91M | -$38.42M | -$30.44M | -$17.72M | -$18.70M | -$39.41M |
| EPS? | $-13.43 | $-16.50 | $-1.94 | $-0.69 | $-30.81 | $-11.52 | $-12.22 | $-8.52 | $-9.33 | $-33.72 |
| Diluted EPS? | $-13.43 | $-16.50 | $-1.94 | $-0.69 | $-30.81 | $-11.52 | $-12.22 | $-8.52 | $-8.86 | $-33.72 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality